Search Results
Results 351 - 400 of 976
< 3 4 5 6 7 8 9 10 11 12 13 >
Siablis Dimitris - - 2007
PURPOSE: To report the 1-year angiographic and clinical outcome from a prospective single-center study investigating the infrapopliteal application of sirolimus-eluting versus bare metal stents in patients with critical limb ischemia (CLI) who underwent below-the-knee endovascular revascularization. METHODS: Stenting was performed as a bailout procedure for suboptimal angioplasty results (flow-limiting dissection, ...
Luthra Suvitesh - - 2007
Deployment of drug-eluting stents has been associated with late thrombosis and restenosis on withdrawal of antiplatelet agents. We report a complication of inflammation and localized coronary artery aneurysms immediately adjacent to the stent after 4 years of implantation. Late chronic inflammatory responses may evolve for up to 4 years after ...
Takano Masamichi - - 2007
Randomized follow-up studies revealed that sirolimus-eluting stent (SES) has an effect on reducing in-stent restenosis resulting from inhibition of neointimal proliferation comparing with bare metal stent (BMS). These data were obtained from separate patients. However, the response against different kinds of these two stents in the same patient had not ...
Kitagawa Toshiro - - 2008
BACKGROUND: A method to objectively detect in-stent restenosis (ISR) with multi-slice computed tomography (MSCT) has not been established yet. We aimed to evaluate the usefulness of measuring coronary lumen density with MSCT to detect ISR. METHODS: Forty-seven coronary stented lesions in 38 patients were evaluated with 16-slice CT (collimation thickness, ...
Sprague Eugene A - - 2007
Percutaneous intervention using balloon angioplasty accompanied by stent implantation has become the predominant procedure to treat occlusive coronary and peripheral vascular disease. Unfortunately, restenosis associated with intimal hyperplasia and arterial remodeling at the stented site occurs within 6 months in 20 to 30% of cases. To address this problem, the ...
Murasato Yoshinobu - - 2007
Restenosis after sirolimuseluting stent (SES) implantation has been reported to be usually focal. We report a case of focal in-stent stenosis discovered angiographically 6 months after SES implantation, despite continuation of dual antiplatelet medication. Continuity and uniform distribution of the struts were confirmed by intravascular ultrasound (IVUS). Material from the ...
Le Mimi Q - - 2007
Coronary artery stent infection is a rare complication of percutaneous intervention. We report a case of fulminant coronary stent infection with Staphylococcus aureus presenting as a pseudoaneurysm of the left circumflex artery following repeated implantation of drug-eluting stents in the setting of multiple episodes of recurrent in-stent restenosis. We speculate ...
Yagi Shusuke - - 2008
Recently, attention has been given to stent fracture (SF) as a risk factor of in-stent restenosis. SF is sometimes revealed at the site of hinge movement (HM). HM synchronized to heart beats might cause chronic mechanical stress of the vessel wall, resulting in chronic inflammation and mobilization of inflammatory cells, ...
Bromberg-Marin Guilherme - - 2007
The increasing use of radiofrequency catheter ablation for the cure of atrial fibrillation has led to iatrogenic pulmonary vein stenosis as a new clinical entity. The optimal diagnostic modality and treatment for pulmonary vein stenosis and restenosis remain unclear. We report the successful treatment of pulmonary vein restenosis following percutaneous ...
Kang Woong Chol - - 2007
BACKGROUND: Although complete coverage of diffuse long coronary lesions has warranted the use of overlapping drug-eluting stents (DESs), the effect of stent overlap with different DESs on the neointimal hyperplasia and whether it would result in dose-related side effects are unknown. METHODS AND RESULTS: Forty-seven consecutive patients, from June 2003 ...
Suzuki N - - 2007
Bifurcation coronary artery disease is a frequent problem faced by interventional cardiologists and it affects approximately 15-20% of patients undergoing percutaneous coronary intervention (PCI). The application of drug-eluting stents (DES) technology to prevent restenosis after PCI represents one of the success stories in cardiology, but DES have not resolved the ...
Park Jong-Seon - - 2007
Recently, reports of stent fracture with focal restenosis have suggested that it is another mechanism of in-stent restenosis after implantation of sirolimus-eluting stents. However, the mechanism by which strut disruption occurs remains unknown. Current reports of in-stent restenosis suggest that fracture of drug-eluting stents is different from bare-metal stents, and ...
Tanimoto Shuzou - - 2007
Small vessel size (<3 mm) has been identified as an independent predictive factor of restenosis after percutaneous coronary intervention when using bare metal stents (BMS). It remains controversial whether BMS placement in small vessels has an advantage over balloon angioplasty in terms of angiographic and clinical outcomes. The advent of ...
Beijk Marcel A M - - 2007
Drug-eluting stents (DES) have been shown to be safe and significantly reduce clinical events and angiographic restenosis in the percutaneous treatment of coronary artery disease. Currently, three DES have been approved in Europe and Northern America: the sirolimus-eluting stent (SES), the paclitaxel-eluting stent (PES) and the zotarolimus-eluting stent (ZES). Everolimus, ...
Li Jian-Jun - - 2007
The development of coronary stent has revolutionized the field of interventional cardiology by reducing the incidence of restenosis after balloon angioplasty. However, the stent has still associated with a serious complication, namely, in-stent restenosis. Although, restenosis following coronary stenting has long been attributed to neointimal proliferation, thrombosis, and negative remodeling, ...
Kibos A - - 2007
In-stent restenosis reflects the interaction of a cascade of molecular and cellular events occurring within the vessel wall. Coronary stenting induces localized injury to the vessel wall, which leads to the release of thrombogenic, vasoactive, and lymphocytes mitogenic factors that result in processes causing re-narrowing at the injured site. Three ...
Mezzapelle Giuseppe - - 2007
The results of using the culotte bifurcation technique have not been promising with regard to bare metal stents; however, some possible advantages with regard to drug-eluting stents (DES) must be taken into account, such as the possibility to stent provisionally, to use lower French sizes, and to completely cover the ...
Barlis Peter - - 2007
Unprotected left main stenosis greater than 50% has traditionally been managed with coronary artery bypass surgery. There is now emerging evidence to support a percutaneous strategy adopting drug-eluting stents, especially in patients at high risk for surgery. This paper will review recent outcomes of both bare-metal and drug-eluting stent use ...
Kishida Ken - - 2007
The development of infected coronary aneurismal fistula following stenting seems exceedingly rare. A sirolimus-eluting stent (SES) was implanted in a 70-year-old male patient for acute coronary syndrome. His fever persisted despite treatment with adapted antibiotics. Coronary angiography and 16-multidetector row computed tomography demonstrated the huge right coronary aneurysm forming a ...
Young John J - - 2007
Percutaneous coronary intervention with drug-eluting stents (DES) is currently the preferred approach to the treatment of obstructive coronary artery disease. Large, randomized trials have demonstrated a significant reduction in the incidence of restenosis and the need for target vessel revascularization following implantation of DES compared with bare-metal stents. Follow-up data ...
Oikawa Yuji - - 2007
PURPOSE: The purpose of this study is to evaluate the acute and chronic results of directional coronary atherectomy (DCA) using the Flexi-Cut atherectomy catheter to treat a left anterior descending artery (LAD) proximal lesion and the device's effect on the ostium of the left circumflex (LCx) immediately and during the ...
Kirtane Ajay J - - 2007
Drug-eluting stents, or intracoronary stents that combine the local delivery of antirestenotic pharmacologic therapies while maintaining the mechanical advantage of bare metal stents over balloon angioplasty alone, are a highly complex technology that have profoundly affected the practice of percutaneous coronary intervention over the last 5 years. These devices were ...
Koutouzis Michael - - 2007
Restenosis after coronary artery stenting is a common phenomenon and represents a topic of great interest. Although a great volume of research is referring to restenosis, still many issues are not fully understood by the cardiological community. Here we present a case of very late restenosis, after a bare metal ...
Ozaki Yukio - - 2007
BACKGROUND: While stent restenosis and late thrombosis still occur even with drug-eluting-stents (DES), there remains a need to explore other strategies for preventing restenosis. METHODS AND RESULTS: Five hundred and twenty-one patients were randomized: 260 to cutting-balloon angioplasty (CBA) before bare-metal stent (CBA-BMS) and 261 to balloon-angioplasty (BA) before BMS ...
Subbotin Vladimir M - - 2007
Despite a prodigious investment of funds, we cannot treat or prevent arteriosclerosis and restenosis, particularly its major pathology, arterial intimal hyperplasia. A cornerstone question lies behind all approaches to the disease: what causes the pathology? I argue that the question itself is misplaced because it implies that intimal hyperplasia is ...
Tamburino Corrado - - 2007
Drug-eluting stents (DES) reduce intimal hyperplasia and restenosis, but they also inhibit stent endothelization, making the vascular surface more thrombogenic. The present report describes two cases of in-stent restenosis after DES deployment at exactly the same sites where subacute stent thrombosis had occurred. Extremely careful follow-up is mandatory after the ...
Assali Abid R - - 2006
OBJECTIVES: The objective of this study was to compare two techniques to treat bifurcation lesions: a single drug-eluting stent (DES) implanted in the main branch combined with balloon dilatation for the side branch vs. stenting of both branches (double stent). BACKGROUND: Percutaneous coronary intervention in coronary bifurcation lesions remains challenging. ...
Ozawa Noriyuki - - 2006
Percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) by the antegrade approach is sometimes difficult, especially in the right coronary artery (RCA). We performed successful PCls following a retrograde approach via a septal branch in 2 patients with CTO in RCA. The method involves leading the retrograde guidewire outside ...
Shafiq Nusrat - - 2006
Cypher (sirolimus-eluting stent) and Taxus (paclitaxel-eluting stent) have been approved for use in percutaneous coronary intervention. Both of the stents have shown superiority over bare metal stents in reducing major adverse cardiac events, restenosis rates and target vessel revascularisation. Results of clinical trials with head-to-head comparison of Taxus and Cypher ...
Caves Jeffrey M - - 2006
Noncoronary atherosclerotic vascular disease, including symptomatic lower extremity peripheral arterial disease (PAD), promises to extract a steadily rising medical and economic toll over the coming decades. Although drug-eluting stents have led to substantial advances in the management of coronary atherosclerosis, endovascular treatment of noncoronary, peripheral arterial lesions continues to yield ...
Suh Soon Yong - - 2007
Although full metal jacket using drug-eluting stent (DES) for a single coronary artery disease has sparsely been described before, there is no report of safety and efficacy of complete metal jacket from left main (LM) to three major coronary arteries. We report a complete metal jacket case using 10 paclitaxel-eluting ...
Kim Seong Hwan - - 2007
Stent thrombosis is a feared complication of percutaneous coronary intervention, although there is a low incidence of thrombotic events following drug-eluting stent implantation. We report a case with cardiogenic shock complicated by acute myocardial infarction due to simultaneous subacute stent thrombosis occurring 3 days after implantation of two sirolimus-eluting stents ...
Uchida Takahiro - - 2006
We assessed the effectiveness of intracoronary brachytherapy and compared treatment effects for the two radiation sources as well as the performance of the procedure in saphenous vein grafts (SVG) and native coronary arteries. Five randomized controlled trials comparing intracoronary brachytherapy with placebo involving a total of 1310 patients were reviewed ...
Lozano Iñigo - - 2006
Restenosis after percutaneous intervention in the left main coronary artery may present as sudden cardiac death. Although drug-eluting stents have demonstrated promising results, there remains the question about appropriate length of the left main artery to be covered with the stent. We describe a patient who received two drug-eluting stents ...
Sawada Takahiro - - 2006
A 76-year-old man presented with an anterior myocardial infarction. Coronary angiography showed 99% stenosis in the left anterior descending artery and total occlusion in the left circumflex artery (LCX). After successful percutaneus coronary intervention (PCI) for segment 7, a staged PCI to the LCX with a distal protection system was ...
Qureshi Adnan I - - 2006
OBJECTIVE: To report the 1-month and intermediate-term results of treatment of symptomatic intracranial stenosis using drug-eluting stents. BACKGROUND: Patients with intracranial stenosis who are at high risk because of either high-grade stenosis or medication failure may have an annual risk of recurrent ischemic events in excess of 40%. Drug-eluting stents ...
Jim Man-Hong - - 2007
Idiopathic isolated ostial left main artery stenosis is a rare disease with uncertain etiology, clinical course and prognosis. We described a young woman with no cardiovascular risk factors, who developed the disease 3 years ago with a bare-metal stent implanted in the left main artery ostium. She presented again with ...
Kupferwasser L I - - 2006
Percutaneous coronary intervention (PCI) of the unprotected left main (LM) artery is currently not recommended as a routine procedure based on the history of inferior outcomes of LM percutaneous transluminal coronary angioplasty and bare metal stenting. Instead, surgical revascularization (coronary artery bypass grafting, CABG) is considered to be the gold ...
Witkowski Adam - - 2006
BACKGROUND: The aim of our study was to test the impact of acute lumen overdilation on neointimal hyperplasia and late lumen size after vascular brachytherapy for in-stent restenosis (ISR). METHODS: Forty-seven ISR lesions located in 47 coronary arteries in 44 consecutive patients underwent beta brachytherapy with serial intravascular ultrasound studies. ...
Presbitero P - - 2006
Drug-eluting stents (DES) have significantly reduced the rates of in-stent restenosis (ISR). As previously observed with bare-metal stents (BMS), either patient's clinical characteristics and lesion morphology may influence the risk of recurrence even with DES. In this review we will focus on the most recent available data on clinical settings ...
Nussbaumer-Ochsner Yvonne - - 2006
PURPOSE: To present a patient in whom severe external carotid artery (ECA) stenosis causing ocular ischemia was treated with a drug-eluting stent. CASE REPORT: A 55-year-old woman with severe, diffuse atherosclerosis presented with impaired left ocular perfusion and amaurosis fugax. Duplex ultrasonography and angiography documented bilateral occlusion at the origin ...
Tian Wen - - 2006
PURPOSE: To investigate the effect of paclitaxel delivered into the adventitia of pig femoral arteries on neointima formation and hyperplasia as well as re-endothelialization. METHODS: Paclitaxel or vehicle was delivered into the adventitia of pig femoral arteries using a needle injection catheter following balloon overstretch. Arteries were then serially examined ...
Kaneda Hideaki - - 2006
OBJECTIVE: The purpose of this study was to identify potential predictors, including clinical, procedural, angiographic, and intravascular ultrasound (IVUS) parameters, for recurrent in-stent restenosis (ISR) following beta-radiation 90Strontium/Yttrium (90Sr/Y) in a large multicenter trial. BACKGROUND: Although adjunct brachytherapy reduces recurrent ISR after primary catheter-based intervention, recurrence of stenosis after brachytherapy ...
Rizik David G - - 2006
OBJECTIVE: The purpose of this study was to evaluate the long-term outcomes of bifurcation coronary lesions treated with a novel technique called "balloon alignment T-stenting". BACKGROUND: The optimal technique for the treatment of bifurcation coronary disease has not yet been established. METHODS: Twenty-six patients with bifurcation coronary lesions were treated ...
Ilkay Erdogan - - 2006
Neointimal hyperplasia is in the forefront in in-stent restenosis. Prevention of in-stent restenosis is possible by reducing and inhibiting the hyperplasia of smooth muscle cells. The authors planned this study to test the hypothesis that when administered orally, mycophenolate mofetil (MMF) could inhibit in-stent neointimal hyperplasia. The study included 14 ...
Gupta Rishi - - 2006
BACKGROUND AND PURPOSE: The use of bare metal stents to treat symptomatic intracranial stenosis may be associated with significant restenosis rates. The advent of drug-eluting stents (DESs) in the coronary circulation has resulted in a reduction of restenosis rates. We report our technical success rate and short-term restenosis rates after ...
Peloschek P - - 2006
OBJECTIVES: To bring out the role of multi-slice spiral CT angiography (MS-CTA) in patient management after endovascular therapy of subclavian artery stenosis. METHODS: Twenty-one consecutive patients with clinically suspected restenosis after endovascular treatment of subclavian artery stenosis or occlusion were included in the study. Eleven patients had been treated with ...
Korovesis Socrates - - 2006
Endeavor (Medtronic Europe SA) is a new zotarolimus-eluting stent with a favourable safety profile reported in early trials. We report a case of subacute thrombosis following deployment of an Endeavor stent in the distal left anterior descending coronary artery, despite optimum loading with and continuation of clopidogrel therapy as well ...
Yang Wei - - 2006
OBJECTIVE: In-stent restenosis is caused by the neointimal hyperplasia, which involves abnormal growth of vascular smooth muscle cells (VSMC). Arsenic trioxide (As2O3) is known to be a potent inhibitor of cell proliferation. We therefore studied the role of an As2O3 eluting stent in the prevention of restenosis in a rabbit ...
Fajadet Jean - - 2006
BACKGROUND: The use of the Endeavor stent might reduce restenosis and stent thrombosis at 9 months. METHODS AND RESULTS: Patients (n = 1197) treated for single coronary artery stenosis were enrolled in a prospective, randomized, double-blind study and randomly assigned to receive the Endeavor zotarolimus-eluting phosphorylcholine polymer-coated stent (n = ...
< 3 4 5 6 7 8 9 10 11 12 13 >